inclusion criteria: * age ≥ 50 years * sars-cov-2 infection positive confirmed by pcr or approved point-of-care test * a score of 5 (hospitalised; oxygen by mask or nasal prongs) or 6 (hospitalised; oxygen by non-invasive ventilation or high flow), but not previously ≥7, on the who clinical progression scale. * signed and dated written informed consent in accordance with ich-gcp and local legislation prior to admission to the trial. * male or female patients. women of childbearing potential (wocbp) and men able to father a child must abstain from male female sex or must use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly during hospitalisation for at least 7 days after last trial drug intake

inclusion criteria: * age ≥ 50 years * sars-cov-2 infection positive confirmed by pcr or approved point-of-care test * a score of 5 (hospitalised; oxygen by mask or nasal prongs) or 6 (hospitalised; oxygen by non-invasive ventilation or high flow), but not previously ≥7, on the who clinical progression scale. * signed and dated written informed consent in accordance with ich-gcp and local legislation prior to admission to the trial. * male or female patients. women of childbearing potential (wocbp) and men able to father a child must abstain from male female sex or must use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly during hospitalisation for at least 7 days after last trial drug intake

inclusion criteria: - age ≥ 50 years - sars-cov-2 infection positive confirmed by pcr or approved point-of-care test - a score of 5 (hospitalised; oxygen by mask or nasal prongs) or 6 (hospitalised; oxygen by non-invasive ventilation or high flow), but not previously ≥7, on the who clinical progression scale. - signed and dated written informed consent in accordance with ich-gcp and local legislation prior to admission to the trial. - male or female patients. women of childbearing potential (wocbp) and men able to father a child must abstain from male female sex or must use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly during hospitalisation for at least 7 days after last trial drug intake

inclusion criteria: - age ≥ 50 years - sars-cov-2 infection positive confirmed by pcr or approved point-of-care test - a score of 5 (hospitalised; oxygen by mask or nasal prongs) or 6 (hospitalised; oxygen by non-invasive ventilation or high flow), but not previously ≥7, on the who clinical progression scale. - signed and dated written informed consent in accordance with ich-gcp and local legislation prior to admission to the trial. - male or female patients. women of childbearing potential (wocbp) and men able to father a child must abstain from male female sex or must use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly during hospitalisation for at least 7 days after last trial drug intake

inclusion criteria: - age ≥ 50 years - sars-cov-2 infection positive confirmed by pcr - a score of 5 (hospitalised; oxygen by mask or nasal prongs) or 6 (hospitalised; oxygen by non-invasive ventilation or high flow), but not previously ≥7, on the who clinical progression scale. - signed and dated written informed consent in accordance with ich-gcp and local legislation prior to admission to the trial. - male or female patients. women of childbearing potential (wocbp) and men able to father a child must abstain from male female sex or must use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly during hospitalisation for at least 7 days after last trial drug intake

inclusion criteria: - age ≥ 50 years - sars-cov-2 infection positive confirmed by pcr - a score of 5 (hospitalised; oxygen by mask or nasal prongs) or 6 (hospitalised; oxygen by non-invasive ventilation or high flow), but not previously ≥7, on the who clinical progression scale. - signed and dated written informed consent in accordance with ich-gcp and local legislation prior to admission to the trial. - male or female patients. women of childbearing potential (wocbp) and men able to father a child must abstain from male female sex or must use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly during hospitalisation for at least 7 days after last trial drug intake